Home / Clinical trials / Tesamorelin
Are there clinical trials for Tesamorelin?
Tesamorelin has 24 registered clinical trials, including 13 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Trial breakdown
By phase
| Phase 2 | 10 |
| Not applicable | 5 |
| Phase 4 | 2 |
| Phase 1 | 2 |
| Phase 3 | 2 |
By status
| Completed | 14 |
| Terminated | 4 |
| Recruiting | 3 |
| Withdrawn | 3 |
Active trials
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)Phase 2 · Recruiting · 120 participants · Hudson Biotech · started 2026-02-02NCT07481734
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVPhase 2 · Recruiting · 100 participants · Massachusetts General Hospital · started 2025-07-10NCT06554717
- Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryPhase 2 · Recruiting · 36 participants · Johns Hopkins University · started 2018-06-01NCT03150511
Most recent registered trials
- Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)Phase 2 · Recruiting · 120 participants · Hudson Biotech · started 2026-02-02NCT07481734
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIVPhase 2 · Recruiting · 100 participants · Massachusetts General Hospital · started 2025-07-10NCT06554717
- Growth Hormone Dynamics and Cardiac Steatosis in HIVCompleted · 23 participants · Massachusetts General Hospital · started 2019-01-30NCT03826160
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular RiskPhase 2 · Completed · 51 participants · Massachusetts General Hospital · started 2019-01-17NCT03375788
- Tesamorelin to Improve Functional Outcomes After Peripheral Nerve InjuryPhase 2 · Recruiting · 36 participants · Johns Hopkins University · started 2018-06-01NCT03150511
- Body Composition and Adipose Tissue in HIVPhase 4 · Terminated · 6 participants · Columbia University · started 2018-02-07NCT03226821
- The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive ImpairmentPhase 1 · Completed · 22 participants · The University of Texas Medical Branch, Galveston · started 2017-07-18NCT02553603
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected PersonsPhase 2 · Completed · 73 participants · University of California, San Diego · started 2017-02-15NCT02572323
- Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current InsomniaPhase 2 · Withdrawn · National Institute of Nursing Research (NINR) · started 2016-10-06NCT02931474
- Tesamorelin Effects on Liver Fat and Histology in HIVNot applicable · Completed · 61 participants · Massachusetts General Hospital · started 2015-07-01NCT02196831
- Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone AnalogueNot applicable · Withdrawn · Massachusetts General Hospital · started 2014-01NCT01632592
- Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®Terminated · 391 participants · Theratechnologies · started 2013-02NCT01579695
Frequently asked questions
Are there clinical trials for Tesamorelin?
Tesamorelin has 24 registered clinical trials, including 13 completed interventional studies and trials reaching Phase 4. Its use in humans is supported by established registered clinical evidence.
Does a registered trial mean the peptide works?
No. Registration means a study was formally listed before or during the research. It says nothing about the result. A completed trial can find no benefit, and many registered studies are never published.
What is the difference between a registered trial and published evidence?
Registration records that a study exists. Publication reports what it found. This page counts registrations, which is the more complete picture of research activity, but it is not a measure of proven effectiveness.
Why do phases matter?
Phase 1 tests safety in a small group. Phase 2 looks for early signs of effect. Phase 3 tests effectiveness against a comparator in a large group, and is what regulators normally require. Phase 4 studies happen after approval. A compound with only Phase 1 trials has not been shown to work.
Source: ClinicalTrials.gov API v2, U.S. National Library of Medicine. Studies where Tesamorelin is registered as an intervention. Last updated 2026-09-23.